GlassScriptPhysician profile
Matthew C Hanggi
NPI 1043278336
$9,057.12
in general payments reported to CMS, 2019-2025
34 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $822 · 2021: $586 · 2022: $1,372 · 2023: $1,629 · 2024: $2,227 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,203.48 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,836.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,258.94 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $979.49 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $892.26 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $592.74 | 2022-2025 | Sotyktu |
| Ucb, INC. | $501.69 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $472.38 | 2019-2025 | Otezla |
| Janssen Biotech, INC. | $391.81 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genentech USA, INC. | $347.63 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $285.05 | 2019-2025 | |
| Genzyme Corporation | $265.42 | 2019-2025 | |
| Pfizer INC. | $211.29 | 2019-2024 | |
| Lilly USA, LLC | $188.30 | 2019-2025 | Taltz, Olumiant |
| Incyte Corporation | $130.96 | 2022-2025 | Opzelura |
| Strata Skin Sciences, INC. | $93.41 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $92.85 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $60.33 | 2019-2025 | Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $49.88 | 2019-2022 | |
| Leo Pharma INC. | $46.92 | 2019-2023 | Adbry |
| Vyne Pharmaceuticals INC. | $42.15 | 2020-2021 | |
| Dusa Pharmaceuticals, INC. | $38.51 | 2019 | |
| Biowound Solutions, INC. | $35.97 | 2025 | Bio-Connekt |
| Organon LLC | $31.96 | 2025 | Vtama |
| Biofrontera INC. | $29.47 | 2022 | |
| Nabriva Therapeutics, Plc | $28.72 | 2022 | |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Boston Scientific Corporation | $22.77 | 2025 | General - Erectile Dysfunction |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.84 | 2024 | Spevigo |
| Surgenex LLC | $18.00 | 2025 | Surmatrix, Pellograft, Ardeograft |
| Celgene Corporation | $16.51 | 2019 | |
| Organogenesis INC. | $15.62 | 2023 | Puraply |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $12.79 | 2019 | |
| Almirall LLC | $12.18 | 2022 | |
| Dermira, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hanggi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.